VICTORIA, British Columbia--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc., (NASDAQ: AUPH / TSX: AUP) today announced that it will release its third quarter 2017 financial results on Tuesday, November 14, 2017, after the market closes. At 4:30 p.m. Eastern Time Aurinia’s management will host a conference call to discuss the company’s financial results for the third quarter 2017 and provide a general business update.
The conference call and webcast is scheduled for November 14, 2017 at 4:30pm EST. In order to participate in the conference call, please dial +1-877-407-9170 (Toll-free U.S. & Canada). An audio webcast can be accessed under "News/Events” through the “Investors” section of the Aurinia corporate website at www.auriniapharma.com. A replay of the webcast will be available on Aurinia’s website.
About Aurinia
Aurinia is a clinical stage
biopharmaceutical company focused on developing and commercializing
therapies to treat targeted patient populations that are suffering from
serious diseases with a high unmet medical need. The company is
currently developing voclosporin, an investigational drug, for the
treatment of LN, FSGS, MCD and DES. The company is headquartered in
Victoria, BC and focuses its development efforts globally. For further
information, see our website at www.auriniapharma.com.
We seek safe harbor.
